Boston Scientific CORP 8-K filings

Boston Scientific reported strong second quarter 2026 results with net sales of $5.442 billion, exceeding guidance and showing robust growth across key segments.

Boston Scientific announced a new global restructuring program expected to incur $700 million to $800 million in pre-tax charges, aiming for $500 million in annual pre-tax expense reductions by 2029.

Boston Scientific has entered into a $2 billion accelerated share repurchase agreement, part of its $5 billion buyback authorization, expected to be completed by June 30, 2026.

Boston Scientific announced a $1.5 billion investment in MiRus LLC, acquiring a 34% stake and an exclusive option to purchase the company's novel transcatheter aortic valve replacement system.

Boston Scientific Corporation's stockholders approved key amendments to its Certificate of Incorporation, including the elimination of supermajority voting provisions and enhanced officer exculpation, at the 2026 Annual Meeting.

Boston Scientific reported strong first-quarter 2026 results, with net sales reaching $5.203 billion, an 11.6% increase year-over-year, exceeding its own guidance.

Boston Scientific reported NEJM-published, ACC.26 late-breaker data showing EKOS superiority in pulmonary embolism and WATCHMAN FLX non-inferior efficacy with superior bleeding outcomes vs NOACs in atrial fibrillation.

Boston Scientific Corporation has entered into new credit agreements totaling $11 billion, including a $6 billion term loan to partially finance the acquisition of Penumbra, Inc., and refinanced its existing credit facility.

Boston Scientific announced the appointment of two new directors to its Board and an additional $4.0 billion authorization for its stock repurchase program, increasing the total to $5.0 billion.

Yoshiaki Fujimori will not seek re-election to Boston Scientific's Board of Directors at the 2026 Annual Meeting, with no disagreement cited.

Boston Scientific reports robust fourth quarter and full year 2025 financial results, surpassing adjusted EPS guidance and announcing strategic acquisitions.

Boston Scientific Corporation has entered into a definitive agreement to acquire Penumbra, Inc. in a mixed cash and stock transaction valued at approximately $14.6 billion.

Boston Scientific announced a definitive agreement to acquire Penumbra, Inc. for an enterprise value of approximately $14.5 billion, expanding its cardiovascular and neurovascular portfolios.

Boston Scientific Corporation's Board of Directors approved its 2026 Annual Bonus Plan and two new performance share programs, aligning executive compensation with company and shareholder performance.

John E. Sununu will not seek re-election to Boston Scientific's Board of Directors at the 2026 Annual Meeting, concluding 17 years of service.

Boston Scientific reported strong third-quarter 2025 financial results, surpassing its own guidance for net sales and adjusted earnings per share.

Boston Scientific Corporation announced the planned retirement of Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, effective December 1, 2025.

Boston Scientific reported exceptional second-quarter 2025 financial results, significantly exceeding guidance with strong sales and earnings per share growth driven by operational excellence and strategic product advancements.

Boston Scientific Corporation announced the discontinuation of its ACURATE neo2 and ACURATE Prime Aortic Valve Systems worldwide, citing prohibitive increases in clinical and regulatory requirements.

Boston Scientific held its 2025 Annual Meeting of Stockholders on May 1, 2025, and all director nominees were elected, executive compensation was approved, Ernst & Young LLP was ratified as the independent accounting firm, and a stockholder proposal for simple majority vote was approved.

Boston Scientific reveals that CFO Dan Brennan will retire and Jon Monson will take over the role, effective June 30, 2025.

Boston Scientific announced robust first-quarter 2025 results, with net sales reaching $4.663 billion and adjusted EPS of $0.75, surpassing previous guidance.

American Medical Systems Europe B.V., a Boston Scientific subsidiary, successfully priced and completed a €1.5 billion offering of senior notes to refinance existing debt and for general corporate purposes.

Charles J. Dockendorff will not seek re-election to Boston Scientific's Board of Directors at the 2025 Annual Meeting.

Boston Scientific announced robust fourth quarter and full year 2024 results, with net sales reaching $4.561 billion for the quarter and $16.747 billion for the year, driven by strong performance across all segments and regions.

Boston Scientific has agreed to a settlement in shareholder derivative lawsuits related to the LOTUS Edge Aortic Valve System recall, which includes corporate governance reforms and a payment of $800,000 in legal fees.

Boston Scientific has approved its 2025 annual bonus plan and two performance share programs for executive officers, focusing on company-wide performance and shareholder value.

Boston Scientific has finalized its acquisition of Axonics, Inc., a medical technology company specializing in devices for urinary and bowel dysfunction, for $3.7 billion.

Boston Scientific has announced the resumption of its AVANT GUARD clinical trial, which studies a new population of drug-naive patients with persistent atrial fibrillation.

Boston Scientific reported robust third-quarter 2024 results, surpassing revenue guidance and achieving significant growth across its cardiovascular segment.